Advertisement

Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes

      Albuminuria is a cardiovascular and renal risk factor in patients with diabetes, patients with hypertension, and the general population. Risk has been shown to increase continuously with increasing urinary albumin levels, starting at levels that once were considered normal. This association is maintained even after adjusting for numerous other factors. Studies also established that a decrease in albuminuria leads to improvement in both cardiovascular and renal outcomes. These data suggest that urinary albumin should be measured routinely and treated to afford cardiovascular and renoprotection.

      Index Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mogensen C.E.
        • Christensen C.K.
        Predicting diabetic nephropathy in insulin-dependent patients.
        N Engl J Med. 1984; 311: 89-93
        • Mogensen C.E.
        Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.
        N Engl J Med. 1984; 310: 356-360
        • Parving H.H.
        • Oxenboll B.
        • Svendsen P.A.
        • Christiansen J.S.
        • Andersen A.R.
        Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion.
        Acta Endocrinol (Copenh). 1982; 100: 550-555
        • Ruggenenti P.
        • Perna A.
        • Gherardi G.
        • et al.
        Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
        Lancet. 1999; 354: 359-364
        • Stuveling E.M.
        • Hillege H.L.
        • Bakker S.J.
        • et al.
        C-Reactive protein and microalbuminuria differ in their associations with various domains of vascular disease.
        Atherosclerosis. 2004; 172: 107-114
        • Verhave J.C.
        • Gansevoort S.J.
        • de Zeeuw D.
        • de Jong P.E.
        An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population.
        Kidney Int Suppl. 2004; 92: S18-S21
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860
        • Parving H.H.
        • Lehnert H.
        • Brochner-Mortensen J.
        • Gomis R.
        • Andersen S.
        • Arner P.
        The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
        N Engl J Med. 2001; 345: 870-878
        • Jones C.A.
        • Francis M.E.
        • Eberhardt M.S.
        • et al.
        Microalbuminuria in the US population.
        Am J Kidney Dis. 2002; 39: 445-459
        • Wu A.Y.
        • Kong N.C.
        • de Leon F.A.
        • et al.
        An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients.
        Diabetologia. 2005; 48: 17-26
        • Parving H.H.
        • Lewis J.B.
        • Wajman A.
        Prevalence and risk factors for microalbuminuria in type 2 diabetic patients.
        Kidney Int. 2006; (in press)
        • American Diabetes Association
        Standards of Medical Care in Diabetes.
        Diabetes Care. 2005; 28 ([published erratum in Diabetes Care 28:990, 2005]): S4-S36
        • National Kidney Foundation
        K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease.
        Am J Kidney Dis. 2002; 39: S1-S266
        • Connell S.J.
        • Hollis S.
        • Tieszen K.L.
        • McMurray J.R.
        • Dornan T.L.
        Gender and the clinical usefulness of the albumin:creatinine ratio.
        Diabet Med. 1994; 11: 32-36
        • Deckert T.
        • Feldt-Rasmussen B.
        • Borch-Johnsen K.
        • Jensen T.
        • Kofoed-Enevoldsen A.
        Albuminuria reflects widespread vascular damage. The Steno hypothesis.
        Diabetologia. 1989; 32: 219-226
        • Ritz E.
        Renal dysfunction as a novel risk factor.
        Kidney Int Suppl. 2005; 93: S25-S28
        • Russo L.M.
        • Comper W.D.
        • Osicka T.M.
        Mechanism of albuminuria associated with cardiovascular disease and kidney disease.
        Kidney Int Suppl. 2004; 92: S67-S68
        • Myers B.D.
        • Winetz J.A.
        • Chui F.
        • Michaels A.S.
        Mechanisms of proteinuria in diabetic nephropathy.
        Kidney Int. 1982; 21: 633-641
        • Deckert T.
        • Feldt-Rasmussen B.
        • Djurup R.
        • Deckert M.
        Glomerular size and charge selectivity in insulin-dependent diabetes mellitus.
        Kidney Int. 1988; 33: 100-106
        • Vernier R.L.
        • Steffes M.W.
        • Sisson-Ross S.
        • Mauer S.M.
        Heparan sulphate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus.
        Kidney Int. 1992; 41: 1070-1080
        • Raats C.J.
        • Van Den Born J.
        • Berden J.H.
        Glomerular heparan sulfate alterations.
        Kidney Int. 2000; 57: 385-400
        • Nickenig G.
        Central role of the AT(1)-receptor in atherosclerosis.
        J Hum Hypertens. 2002; 16: S26-S33
        • Schieffer B.
        • Schieffer E.
        • Hilfiker-Kleiner D.
        • et al.
        Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques.
        Circulation. 2000; 101: 1372-1378
        • Warnholtz A.
        • Nickenig G.
        • Schulz E.
        • et al.
        Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis.
        Circulation. 1999; 99: 2027-2033
        • Morawietz H.
        • Rueckschloss U.
        • Niemann B.
        • et al.
        Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.
        Circulation. 1999; 100: 899-902
        • Graninger M.
        • Reiter R.
        • Drucker C.
        • Minar E.
        • Jilma B.
        Angiotensin receptor blockade decreases markers of vascular inflammation.
        J Cardiovasc Pharmacol. 2004; 44: 335-339
        • Miller J.A.
        Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus.
        J Am Soc Nephrol. 1999; 10: 1778-1785
        • Taniwaki H.
        • Ishimura E.
        • Kawagishi T.
        • et al.
        Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes.
        Diabetes Care. 2003; 26: 132-137
        • Buter H.
        • Navis G.
        • Dullaart R.P.
        • de Zeeuw D.
        • de Jong P.E.
        Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
        Nephrol Dial Transplant. 2001; 16: 771-775
        • Viberti G.
        • Wheeldon N.M.
        Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus.
        Circulation. 2002; 106: 672-678
        • Kopyt N.P.
        Slowing progression along the renal disease continuum.
        J Am Osteopath Assoc. 2005; 105: 207-215
        • Jafar T.H.
        • Stark P.C.
        • Schmid C.H.
        • et al.
        Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis.
        Ann Intern Med. 2003; 139: 244-252
        • Atkins R.C.
        • Briganti E.M.
        • Lewis J.B.
        • et al.
        Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
        Am J Kidney Dis. 2005; 45: 281-287
        • Locatelli F.
        • Marcelli D.
        • Comelli M.
        • et al.
        • Northern Italian Cooperative Study Group
        Proteinuria and blood pressure as causal components of progression to end-stage renal failure.
        Nephrol Dial Transplant. 1996; 11: 461-467
        • Iseki K.
        • Ikemiya Y.
        • Iseki C.
        • Takishita S.
        Proteinuria and the risk of developing end-stage renal disease.
        Kidney Int. 2003; 63: 1468-1474
        • Keane W.F.
        • Brenner B.M.
        • de Zeeuw D.
        • et al.
        The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy.
        Kidney Int. 2003; 63: 1499-1507
        • de Zeeuw D.
        • Remuzzi G.
        • Parving H.H.
        • et al.
        Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy.
        Kidney Int. 2004; 65: 2309-2320
        • Chan J.C.
        • Wat N.M.
        • So W.Y.
        • et al.
        Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
        Diabetes Care. 2004; 27: 874-879
        • Viberti G.C.
        • Hill R.D.
        • Jarrett R.J.
        • Argyropoulos A.
        • Mahmud U.
        • Keen H.
        Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus.
        Lancet. 1982; 1: 1430-1432
        • Mogensen C.E.
        Microalbuminuria as a predictor of clinical diabetic nephropathy.
        Kidney Int. 1987; 31: 673-689
        • Berrut G.
        • Bouhanick B.
        • Fabbri P.
        • et al.
        Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension.
        Clin Nephrol. 1997; 48: 92-97
        • Nosadini R.
        • Tonolo G.
        Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes.
        J Nephrol. 2003; 16: S42-S47
        • Agodoa L.Y.
        • Appel L.
        • Bakris G.L.
        • et al.
        Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis.
        JAMA. 2001; 285: 2719-2728
        • Pontremoli R.
        • Leoncini G.
        • Ravera M.
        • et al.
        Microalbuminuria, cardiovascular, and renal risk in primary hypertension.
        J Am Soc Nephrol. 2002; 13: S169-S172
        • Bigazzi R.
        • Bianchi S.
        • Baldari D.
        • Campese V.M.
        Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension.
        J Hypertens. 1998; 16: 1325-1333
        • Dell’Omo G.
        • Penno G.
        • Giorgi D.
        • Di Bello V.
        • Mariani M.
        • Pedrinelli R.
        Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men.
        Am J Kidney Dis. 2002; 40: 1-8
        • Pontremoli R.
        • Sofia A.
        • Ravera M.
        • et al.
        Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications.
        Hypertension. 1997; 30: 1135-1143
        • Ahmad J.
        • Shafique S.
        • Abidi S.M.
        • Parwez I.
        Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects.
        Diabetes Res Clin Pract. 2003; 60: 131-138
        • De Boer E.
        • Navis G.
        • Tiebosch A.T.
        • De Jong P.E.
        • de Zeeuw D.
        Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in Adriamycin nephrotic rats.
        J Am Soc Nephrol. 1999; 10: 2359-2366
        • The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
        Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.
        Lancet. 1997; 349: 1857-1863
        • Ciavarella A.
        • Mustacchio A.
        • Silletti A.
        • et al.
        Low-dose angiotensin converting enzyme inhibitors.
        Eur J Med. 1992; 1: 268-272
        • Lewis E.J.
        • Hunsicker L.G.
        • Bain R.P.
        • Collaborative Study Group
        The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
        N Engl J Med. 1993; 329: 1456-1462
        • Heart Outcomes Prevention Evaluation Study Investigators
        Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus.
        Lancet. 2000; 355 ([erratum in Lancet 356:860, 2000]): 253-259
        • Rossing K.
        • Schjoedt K.J.
        • Jensen B.R.
        • Boomsma F.
        • Parving H.H.
        Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
        Kidney Int. 2005; 68: 1190-1198
        • Crippa G.
        Microalbuminuria in essential hypertension.
        J Hum Hypertens. 2002; 16: S74-S77
        • Bigazzi R.
        • Bianchi S.
        • Baldari D.
        • Sgherri G.
        • Baldari G.
        • Campese V.M.
        Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension.
        Am J Hypertens. 1993; 6: 108-113
        • Bianchi S.
        • Bigazzi R.
        • Baldari G.
        • Campese V.M.
        Microalbuminuria in patients with essential hypertension.
        Am J Med. 1992; 93: 525-528
        • Bianchi S.
        • Bigazzi R.
        • Baldari G.
        • Campese V.M.
        Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker.
        Am J Hypertens. 1991; 4: 291-296
        • Shionoiri H.
        • Sugimoto K.
        • Kosaka T.
        • et al.
        Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension.
        Hypertens Res. 1998; 21: 81-87
        • Monster T.B.
        • Janssen W.M.
        • de Jong P.E.
        • de Jong-van den Berg L.T.
        The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.
        Br J Clin Pharmacol. 2002; 53: 31-36
        • Lea J.
        • Greene T.
        • Hebert L.
        The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease.
        Arch Intern Med. 2005; 165: 947-953
        • Maschio G.
        • Alberti D.
        • Janin G.
        • et al.
        • The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group
        Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.
        N Engl J Med. 1996; 334: 939-945
        • Marre M.
        • Lievre M.
        • Chatellier G.
        • Mann J.F.
        • Passa P.
        • Menard J.
        Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin.
        BMJ. 2004; 328 ([erratum in BMJ 328:686, 2004]): 495
        • Vaur L.
        • Gueret P.
        • Lievre M.
        • Chabaud S.
        • Passa P.
        Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria.
        Diabetes Care. 2003; 26 ([erratum in Diabetes Care 26:2489, 2003]): 855-860
        • Yuyun M.F.
        • Khaw K.T.
        • Luben R.
        • et al.
        Microalbuminuria and stroke in a British population.
        J Intern Med. 2004; 255: 247-256
        • Yuyun M.F.
        • Khaw K.T.
        • Luben R.
        • et al.
        A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population.
        Am J Epidemiol. 2004; 159: 284-293
        • Yuyun M.F.
        • Khaw K.T.
        • Luben R.
        • et al.
        Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population.
        Int J Epidemiol. 2004; 33: 189-198
        • Culleton B.F.
        • Larson M.G.
        • Parfrey P.S.
        • Kannel W.B.
        • Levy D.
        Proteinuria as a risk factor for cardiovascular disease and mortality in older people.
        Am J Med. 2000; 109: 1-8
        • Gerstein H.C.
        • Mann J.F.
        • Yi Q.
        • et al.
        Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
        JAMA. 2001; 286: 421-426
        • Mann J.F.
        • Lonn E.M.
        • Yi Q.
        • et al.
        Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency.
        Kidney Int. 2004; 65: 1375-1380
        • Anavekar N.S.
        • Gans D.J.
        • Berl T.
        Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension.
        Kidney Int Suppl. 2004; 92: S50-S55
        • Wachtell K.
        • Ibsen H.
        • Olsen M.H.
        • et al.
        Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy.
        Ann Intern Med. 2003; 139: 901-906
        • Olsen M.H.
        • Wachtell K.
        • Bella J.N.
        • et al.
        Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
        Am J Cardiol. 2004; 94: 1076-1080
        • Miettinen H.
        • Haffner S.M.
        • Lehto S.
        • Ronnemaa T.
        • Pyorala K.
        • Laakso M.
        Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects.
        Stroke. 1996; 27: 2033-2039
        • Jensen J.S.
        • Feldt-Rasmussen B.
        • Strandgaard S.
        • Schroll M.
        • Borch-Johnsen K.
        Arterial hypertension, microalbuminuria, and risk of ischemic heart disease.
        Hypertension. 2000; 35: 898-903
        • Nakamura S.
        • Kawano Y.
        • Inenaga T.
        • et al.
        Microalbuminuria and cardiovascular events in elderly hypertensive patients without previous cardiovascular complications.
        Hypertens Res. 2003; 26: 603-608
        • Rachmani R.
        • Levi Z.
        • Lidar M.
        • Slavachevski I.
        • Half-Onn E.
        • Ravid M.
        Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus.
        Diabetes Res Clin Pract. 2000; 49: 187-194
        • Damsgaard E.M.
        • Froland A.
        • Jorgensen O.D.
        • Mogensen C.E.
        Microalbuminuria as predictor of increased mortality in elderly people.
        BMJ. 1990; 300: 297-300
        • Yudkin J.S.
        • Forrest R.D.
        • Jackson C.A.
        Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.
        Lancet. 1988; 2: 530-533
        • Hillege H.L.
        • Fidler V.
        • Diercks G.F.
        • et al.
        Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
        Circulation. 2002; 106: 1777-1782
        • Arnlov J.
        • Evans J.C.
        • Meigs J.B.
        • et al.
        Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals.
        Circulation. 2005; 112: 969-975
        • Wang T.J.
        • Evans J.C.
        • Meigs J.B.
        • et al.
        Low-grade albuminuria and the risks of hypertension and blood pressure progression.
        Circulation. 2005; 111: 1370-1376
        • Klausen K.
        • Borch-Johnsen K.
        • Feldt-Rasmussen B.
        • et al.
        Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes.
        Circulation. 2004; 110: 32-35
        • HOPE Study Investigators
        The HOPE (Heart Outcomes Prevention Evaluation) Study.
        Can J Cardiol. 1996; 12: 127-137
        • Jose P.
        • Tomson C.
        • Skali H.
        Influence of proteinuria on outcomes and response to ACE inhibitor therapy after myocardial infarction.
        Eur Heart J. 2005; 26 (abstr): S48A
        • Arnold J.M.
        • Yusuf S.
        • Young J.
        • et al.
        Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
        Circulation. 2003; 107: 1284-1290
        • Ibsen H.
        • Olsen M.H.
        • Wachtell K.
        • et al.
        Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients.
        Hypertension. 2005; 45: 198-202
        • Asselbergs F.W.
        • Diercks G.F.
        • Hillege H.L.
        • et al.
        Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
        Circulation. 2004; 110: 2809-2816
        • Jacobsen P.
        • Andersen S.
        • Jensen B.R.
        • Parving H.H.
        Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
        J Am Soc Nephrol. 2003; 14: 992-999
        • Jacobsen P.
        • Andersen S.
        • Rossing K.
        • Jensen B.R.
        • Parving H.H.
        Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
        Kidney Int. 2003; 63: 1874-1880
        • Nakao N.
        • Yoshimura A.
        • Morita H.
        • Takada M.
        • Kayano T.
        • Ideura T.
        Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE).
        Lancet. 2003; 361 ([erratum in Lancet 361:1230, 2003]): 117-124
        • Sinzinger H.
        • Kritz H.
        • Furberg C.D.
        Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.
        Med Sci Monit. 2003; 9: PI88-PI92
        • de Zeeuw D.
        Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?.
        Kidney Int Suppl. 2004; 92: S2-S6
        • Gambaro G.
        • Kinalska I.
        • Oksa A.
        • et al.
        Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients.
        J Am Soc Nephrol. 2002; 13: 1615-1625
        • Giustina A.
        • Perini P.
        • Desenzani P.
        • et al.
        Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients.
        Diabetes. 1998; 47: 423-430
        • Lewis E.J.
        • Lewis J.B.
        • Hunsicker L.G.
        Interim analysis of a pilot trial of sulodexide in type 2 diabetic nephropathy with microalbuminuria. Free communication. 2005 (Abstract presented at: American Society of Nephrology 38th Annual Renal Week. F-FC092 Available at: www.abstracts2view.com/asn. Accessed January 1, 2006.)
        • Azizi M.
        • Menard J.
        Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
        Circulation. 2004; 109: 2492-2499
        • van Paassen P.
        • de Zeeuw D.
        • Navis G.
        • de Jong P.E.
        Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.
        Nephrol Dial Transplant. 2000; 15: 637-643
        • Pilz B.
        • Shagdarsuren E.
        • Wellner M.
        • et al.
        Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
        Hypertension. 2005; 46: 569-576
        • Epstein M.
        Aldosterone receptor blockade and the role of eplerenone.
        Nephrol Dial Transplant. 2003; 18: 1984-1992
        • Cerasola G.
        • Cottone S.
        • Mule G.
        • et al.
        Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.
        J Hypertens. 1996; 14: 915-920
        • Bigazzi R.
        • Bianchi S.
        • Nenci R.
        • Baldari D.
        • Baldari G.
        • Campese V.M.
        Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria.
        J Hum Hypertens. 1995; 9: 827-833
        • Mule G.
        • Cottone S.
        • Vadala A.
        • et al.
        Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients.
        J Intern Med. 2004; 256: 22-29
        • Fisher N.D.
        • Hollenberg N.K.
        Renin inhibition.
        J Am Soc Nephrol. 2005; 16: 592-599